Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupivacaine controlled release - Bausch Health Companies

Next Previous
Drug Profile

Bupivacaine controlled release - Bausch Health Companies

Alternative Names: Bupivacaine extended release - Bausch Health Companies; Bupivacaine solution - Bausch Health Companies; Optesia; POSIDUR; POSIMIR; SABER®-bupivacaine

Latest Information Update: 17 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DURECT Corporation
  • Developer Bausch Health Companies; Takeda Pharmaceuticals International GmbH
  • Class Amides; Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Piperidines; Small molecules; Xylenes
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Postoperative pain

Highest Development Phases

  • Marketed Postoperative pain

Most Recent Events

  • 11 Sep 2025 DURECT Corporation has been acquired and merged into Bausch Health Companies
  • 27 Sep 2022 Launched for Postoperative pain in USA (SC)
  • 02 Aug 2022 DURECT has extending US patent coverage for bupivacaine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top